» Authors » Stephen J Elliman

Stephen J Elliman

Explore the profile of Stephen J Elliman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 263
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanz-Nogues C, Keane A, Creane M, Hynes S, Chen X, Lyons C, et al.
Stem Cells . 2024 Sep; 42(11):976-991. PMID: 39283740
Peripheral arterial disease (PAD) is associated with lower-extremity muscle wasting. Hallmark features of PAD-associated skeletal muscle pathology include loss of skeletal muscle mass, reduced strength and physical performance, increased inflammation,...
2.
Du S, Elliman S, Zeugolis D, OBrien T
Int J Biol Macromol . 2023 Aug; 251:126353. PMID: 37591431
Cell sheet tissue engineering requires prolonged in vitro culture for the development of implantable devices. Unfortunately, lengthy in vitro culture is associated with cell phenotype loss and substantially higher cost...
3.
Perico N, Remuzzi G, Griffin M, Cockwell P, Maxwell A, Casiraghi F, et al.
J Am Soc Nephrol . 2023 Aug; 34(10):1733-1751. PMID: 37560967
Significance Statement: Mesenchymal stromal cells (MSCs) may offer a novel therapy for diabetic kidney disease (DKD), although clinical translation of this approach has been limited. The authors present findings from...
4.
Gonzalez H, McCarthy S, Masterson C, Byrnes D, Sallent I, Horan E, et al.
Stem Cell Res Ther . 2023 Jun; 14(1):151. PMID: 37280647
Background: Mesenchymal stem cell (MSC) derived extracellular vesicles (EVs) have been proposed as an alternative to cell therapy, creating new possible delivery modalities such as nebulisation. We wished to investigate...
5.
Barry L, Crealey G, Cockwell P, Elliman S, Griffin M, Maxwell A, et al.
PLoS One . 2022 Nov; 17(11):e0274136. PMID: 36331936
Background And Objectives: To simulate the cost-effectiveness of Mesenchymal Stromal Cell (MSC) therapy compared to sodium/glucose co-transporter 2 inhibitors (SGLT2i) or usual care (UC) in treating patients with Diabetic Kidney...
6.
Fazekas B, Alagesan S, Watson L, Ng O, Conroy C, Catala C, et al.
Stem Cell Rev Rep . 2022 Jan; 18(4):1444-1460. PMID: 35013938
Mesenchymal stromal cells (MSCs) ameliorate pre-clinical sepsis and sepsis-associated acute kidney injury (SA-AKI) but clinical trials of single-dose MSCs have not indicated robust efficacy. This study investigated immunomodulatory effects of...
7.
Gonzalez H, Keane C, Masterson C, Horie S, Elliman S, Higgins B, et al.
Int J Mol Sci . 2020 Nov; 21(21). PMID: 33158246
Mesenchymal stromal cells (MSCs) have a multimodal, immunomodulatory mechanism of action and are now in clinical trials for single organ and systemic sepsis. However, a number of practicalities around source,...
8.
Loftus P, Watson L, Deedigan L, Camarillo-Retamosa E, Dwyer R, OFlynn L, et al.
Int J Cancer . 2020 Nov; 148(5):1245-1259. PMID: 33152121
Tumour stromal cells support tumourigenesis. We report that Syndecan-2 (SDC2) is expressed on a nonepithelial, nonhaematopoietic, nonendothelial stromal cell population within breast cancer tissue. In vitro, syndecan-2 modulated TGFβ signalling...
9.
Browe D, Coleman C, Barry F, Elliman S
Sci Rep . 2019 Sep; 9(1):13274. PMID: 31527619
Articular cartilage lacks an intrinsic repair capacity and due to the ability of mesenchymal stem cells (MSCs) to differentiate into chondrocytes, MSCs have been touted as a cellular source to...
10.
Lohan P, Treacy O, Morcos M, Donohoe E, Odonoghue Y, Ryan A, et al.
Stem Cells . 2018 May; 36(8):1210-1215. PMID: 29726063
Mesenchymal stem/stromal cells (MSC) are an immunomodulatory cell population which are under preclinical and clinical investigation for a number of inflammatory conditions including transplantation. In this study, a well-established rat...